HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
NY1DL1RLZvysQyqC